Detalhe da pesquisa
1.
First Three Years' Experience of Mucopolysaccharidosis Type-I Newborn Screening in California.
J Pediatr
; 263: 113644, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516270
2.
Damaged goods?: an empirical cohort study of blood specimens collected 12 to 23 hours after birth in newborn screening in California.
Genet Med
; 18(3): 259-64, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26656653
3.
Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I.
Int J Neonatal Screen
; 9(1)2023 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36975849
4.
California's experience with SMA newborn screening: A successful path to early intervention.
J Neuromuscul Dis
; 9(6): 777-785, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36278357
5.
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
J Mol Endocrinol
; 32(2): 425-36, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15072549
6.
A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
Metabolism
; 52(8): 1012-8, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12898466
7.
Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process.
Clin Chim Acta
; 412(11-12): 873-9, 2011 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21216241
8.
Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents.
Bioorg Med Chem
; 11(18): 4059-67, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12927868